Addition of nimotuzumab to concurrent chemoradiotherapy after induction chemotherapy improves outcomes of patients with locally advanced nasopharyngeal carcinoma

CONCLUSION: The addition of nimotuzumab to CCRT after IC in LANPC has shown promising results in improving treatment outcomes and acceptable toxicities.PMID:38576484 | PMC:PMC10991775 | DOI:10.3389/fphar.2024.1366853

Source: Cancer Control - April 5, 2024 Category: Cancer & Oncology Authors: Run-Jie Wang Rui-Quan Ke Yi-Feng Yu Guan-Zhong Lu San-Gang Wu Source Type: research